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Summary
Background: In response to DNA damage, cells undergo
either cell-cycle arrest or apoptosis, depending on the extent
of damage and the cell’s capacity for DNA repair. Cell-cycle
arrest induced by double-stranded DNA breaks depends on
activation of the ataxia-telangiectasia (ATM) protein kinase,
which phosphorylates cell-cycle effectors such as Chk2 and
p53 to inhibit cell-cycle progression. ATM is recruited to dou-
ble-stranded DNA breaks by a complex of sensor proteins, in-
cluding Mre11/Rad50/Nbs1, resulting in autophosphorylation,
monomerization, and activation of ATM kinase.
Results: In characterizing Aven protein, a previously reported
apoptotic inhibitor, we have found that Aven can function as an
ATM activator to inhibit G2/M progression. Aven bound to
ATM and Aven overexpressed in cycling Xenopus egg extracts
prevented mitotic entry and induced phosphorylation of ATM
and its substrates. Immunodepletion of endogenous Aven
allowed mitotic entry even in the presence of damaged DNA,
and RNAi-mediated knockdown of Aven in human cells pre-
vented autophosphorylation of ATM at an activating site
(S1981) in response to DNA damage. Interestingly, Aven is
*Correspondence: kornb001@mc.duke.edu
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9Current address: Rosetta Inpharmatics, Kirkland, WA 98034also a substrate of the ATM kinase. Mutation of ATM-mediated
phosphorylation sites on Aven reduced its ability to activate
ATM, suggesting that Aven activation of ATM after DNA dam-
age is enhanced by ATM-mediated Aven phosphorylation.
Conclusions: These results identify Aven as a new ATM acti-
vator and describe a positive feedback loop operating be-
tween Aven and ATM. In aggregate, these findings place
Aven, a known apoptotic inhibitor, as a critical transducer of
the DNA-damage signal.
Introduction
Entry into mitosis, driven by Cdc2/Cyclin B, can be inhibited
after DNA damage by DNA-responsive checkpoints [1, 2].
These signaling pathways employ DNA-damage sensors and
transducers to inhibit cell-cycle effectors [3]. To prevent mitotic
entry, checkpoint pathways target the critical Cdc2 regulators,
Wee1 and Cdc25 [4–7], which inhibit and activate Cdc2/Cyclin
B, respectively [1, 2, 8]. When checkpoints are operative, Chk1/
Chk2 kinases phosphorylate Wee1 and Cdc25, inducing acti-
vation and inhibition, respectively, of the downstream mole-
cules [6, 9]. Cdc25 is phosphorylated and inhibited by Chk1/
Chk2-mediated phosphorylation at S287 (Xenopus number-
ing), which promotes docking of 14-3-3 [10–14]. Cdc25 activa-
tion depends upon active 14-3-3 removal and subsequent
PP1-mediated S287 dephosphorylation [15–17].
Activation of Chk1/Chk2 requires DNA-damage-mediated
activation of upstream members of the phosphoinositide-3-ki-
nase-related kinases (PIKKs), ATM and ATR [11, 18–21]. In the
case of double-stranded DNA breaks, a complex of proteins,
including Mre11, Rad50, and Nbs1 (the MRN complex), accu-
mulates at DNA-damage sites to form foci. ATM is then re-
cruited to the MRN complex, where it autophosphorylates at
S1981 and is converted from an inactive dimer into an active
monomer [22–26]. It is likely that there are other, as-yet-un-
identified factors that participate in ATM regulation.
A variety of cellular processes have been reconstituted in
extracts prepared from Xenopus eggs [27–29]. Cycling egg
extracts [30], which oscillate between S and M phases of the
cell cycle, can recapitulate DNA-damage-responsive check-
points in vitro; addition of annealed oligonucleotides mimick-
ing damaged DNA prevents M phase entry, arresting extracts
with inactive Cyclin B/Cdc2 complexes [18, 31, 32]. Incubation
of egg extracts on the bench for 4–6 hr results in cytochrome c
release from mitochondria and caspase activation [33–35].
These cycling and apoptotic properties of the Xenopus egg
extracts make them well-suited for the analysis of factors
implicated in cell-cycle progression or apoptosis.
We wished to use egg extracts to analyze the function of
a previously reported apoptotic inhibitor, Aven. Human Aven
was originally identified as an interactor of the anti-apoptotic
protein Bcl-xL. Aven mRNA was detected in all adult tissues
but was most abundant in heart, skeletal muscle, kidney, liver,
pancreas, and testis. Although the predicted molecular weight
of Aven is 38.6 kDa, the apparent molecular weight of Aven
derived from HeLa cells, where it can be found in both cyto-
plasmic and nuclear fractions, is 55 kD. Aven overexpression
is reported to be associated with poor prognosis in childhood
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action with Bcl-xL, Aven is reported to interact with and inhibit
Apaf-1 oligomerization, which is required for activation of
caspase-9 [40, 41]. The molecular mechanism underlying the
ability of Aven to impede Apaf-1 oligomerization and the signif-
icance of Aven’s association with Bcl-xL are not clear. More-
over, the possibility that Aven might have additional functions
has not been explored.
We have now found that Aven protein is a potent activator of
ATM,critical for its DNA-damage-inducedactivation.Avenover-
expression in cycling egg extracts induced phosphorylation of
Figure 1. Aven Overexpression Delays Mitotic
Entry
(A) Cycling Xenopus egg extracts were supple-
mented with mRNA encoding full-length human
Aven (hAven) or an equal volume buffer control.
Samples were withdrawn at the indicated times
and assayed for their ability to phosphorylate
histone H1 in the presence of [g-32P] ATP.
(B) mRNA encoding hAven, DN72hAven or Xeno-
pus b-globin (x- ßGlobin), or buffer control were
added to cycling Xenopus egg extracts. Aliquots
of extracts were withdrawn at the indicated times
and assayed as in (A).
(C and D) His-DN72hAven protein or GST control
was added to interphase extracts and incubated
for 30 min. After the addition of nondegradable
CyclinB1, aliquots were taken at the indicated
times (C) for visualization of nuclear-envelope
breakdown and chromatin condensation by fluo-
rescence microscopy (Hoechst DNA stain) and
(D) to assay histone H1 phosphorylation. (C) Bot-
tom: represents the average of three replicates.
(E) Cycling extracts were incubated with mRNA
encoding Xenopus Aven (xAven) or buffer, and
aliquots were taken at the indicated times and
assayed as in (A).
(F) Forty stage-VI oocytes were injected with
mRNAs encoding x-ßGlobin, xAven, or hAven.
After 12 hr, oocytes were treated with progester-
one and scored for germinal-vesicle breakdown
(GVBD).
Data shown in this and all subsequent figures are
the result of at least three repetitions.
ATM substrates independent of DNA
damage, and depletion of Aven abro-
gated G2/M arrest in response to DNA
damage. Similarly, RNAi knockdown of
Aven in mammalian cells dampened
DNA-damage-induced ATM activation.
Phosphorylation of Aven byATM ina pos-
itive feedback loop appears to be re-
quired for its full potency as an ATM acti-
vator. These data implicate the apoptotic
regulator Aven as an integral component
of the DNA-damage-responsive-check-
point pathway.
Results
Aven Inhibits Entry into Mitosis
To further analyze the apoptotic function
of Aven, we wished to overexpress Aven
protein and determine its effects on cas-
pase activation in Xenopus egg extracts.
However, when we added excess mRNA encoding human
Aven protein (approximately doubling the endogenous Aven
concentration of 80 nM) to cycling egg extracts, we found
that Aven had a profound effect on cell-cycle progression.
The extracts expressing excess Aven either failed to enter mi-
tosis or was significantly delayed in mitotic entry, as evidenced
by a dampening of histone H1 kinase activation and an inhibi-
tion of nuclear-envelope breakdown and chromatin condensa-
tion (Figures 1A and 1B and data not shown). To confirm that
the protein product of Aven mRNA was responsible for cell-
cycle inhibition, recombinant His-tagged human Aven protein
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culty for protein purification, was added to interphase egg ex-
tracts treated with recombinant Cyclin B to drive mitotic entry.
His-DN72 Aven protein prevented nuclear-envelope break-
down, chromatin condensation, and activation of Cdc2/Cyclin
B (Figures 1C and 1D). Similar results were obtained when
Aven mRNA lacking codons 2–72 was added to cycling ex-
tracts (Figure 1B), indicating that the Gly-rich N-terminal region
was not required for the cell-cycle arrest. To demonstrate that
Xenopus Aven, which shares 42% amino acid sequence iden-
tity with human Aven, could also inhibit mitotic entry, we
cloned the Xenopus Aven cDNA (Figure S1, available online)
and repeated our experiments analyzing the effects of full-
length Xenopous Aven overexpression on M-phase entry. As
shown in Figure 1E, Xenopus Aven acted similarly to human
Aven in retarding mitotic entry. To assay the effects of Aven
in an intact cell, we tested whether Aven overexpression would
impede progesterone-induced oocyte maturation (progres-
sion through G2/M). Expression of either Xenopus or human
Aven mRNAs, but not of control Xenopus b-globin mRNA,
markedly delayed M-phase entry in oocytes (Figure 1F).
Aven Inhibits Activation of Cdc2/Cyclin B
Aven’s ability to inhibit histone H1-directed kinase activity
suggested that Aven might inhibit Cdc2 directly. However,
as shown in Figure 2A, addition of Aven protein to purified
Cdc2/Cyclin B had no effect on Cdc2 kinase activity, even
at protein levels as high as 320 nM. Cdc2 activity is controlled
by Cyclin levels [42, 43] and through inhibitory Y15 phosphor-
ylation of Cdc2 [1, 2]. Cyclin B protein synthesis was unaf-
fected by Aven (data not shown). In contrast, Cdc2 dephos-
phorylation on Y15, which occurred on schedule in control
extracts, was absent in the Aven-supplemented extracts,
consistent with a role for Aven as a mitotic inhibitor
(Figure 2B).
Maintenance of Cdc2 Y15 phosphorylation could result from
sustained activation of Y15-directed kinases (Wee1 and Myt1),
from inhibition of the Y15-directed phosphatase, Cdc25, or
both [1]. Activation of Cdc25 at mitotic entry requires T138
phosphorylation, which promotes removal of bound 14-3-3
and allows the reversal of inhibitory S287 phosphorylation on
Cdc25 [15]. To determine whether Aven could modulate
Cdc25, we monitored Cdc25 modifications in the presence
and absence of increased Aven protein. As shown in Figure 2C,
in the presence of Aven protein, T138 phosphorylation was not
observed, Cdc25 remained 14-3-3-bound, and S287 remained
phosphorylated, consistent with a role for Aven in controlling
upstream factors that regulate Cdc25 (Figure 2C). Moreover,
expression of an S287A mutant Cdc25, but not of wild-type
(WT) Cdc25, in cycling extracts could override the effects of
Aven addition, allowing Cdc2 Y15 dephosphorylation despite
Aven overexpression (Figure 2D).
Although Aven impinged on Cdc25 activation, this did not
preclude a role for Aven in the activation of Wee1 (or Myt1).
In unperturbed extracts, Wee1 and Myt1 activity is high during
interphase and drops at mitotic entry to allow Cdc2 activation
[44]. Remarkably, addition of recombinant Aven to extracts
already in mitosis allowed suppression of Cdc2 activity and re-
phosphorylation of Y15 (Figures 2E and 2F). Given that Wee1
and Myt1 are normally turned off in mitotic extracts and
Cdc2 was fully dephosphorylated prior to Aven addition, these
results strongly suggest that Aven can modulate both the
Cdc25 and the Wee1 and Myt1 arms of the Cdc2-regulatory
pathway.Aven Interacts with and Activates ATM
Because Aven appeared to control Cdc25 at known points of
DNA-responsive-checkpoint regulation (T138 and S287) and
because both Wee1 and Cdc25 might be modulated down-
stream of Aven, we speculated that Aven might be an up-
stream regulator of factors that normally participate in DNA-
responsive-checkpoint signaling. In support of this, we found
that both the inhibitor of Chk kinases, UCN-01, and the ATM/
ATR inhibitor, caffeine, could override the ability of Aven to in-
duce cell-cycle arrest prior to mitotic entry (Figures 3A and 3B).
Using Aven residues 1-289 as bait in a yeast two-hybrid
screen of a cDNA library from 3-week-old rat brain (provided
by Paul Worley; note that the C-terminal domain was elimi-
nated because it had the intrinsic ability to activate transcrip-
tion), we identified the C-terminal kinase domain (wresidues
2500–3000) of ATM kinase as a potential Aven interactor. The
binding of Aven both to the kinase domain and to full-length
ATM was confirmed by coimmunoprecipitation experiments
in transfected mammalian cells. Furthermore, both full-length
Aven and DN72-Aven interacted with ATM (Figure 3C and
data not shown). Moreover, GST-Aven-coupled glutathione
beads retrieved ATM from Xenopus interphase extracts, and
this band disappeared upon immunodepletion of ATM (Fig-
ure 3D). Given these findings, we examined whether Aven re-
quires ATM for inhibition of the cell cycle. Aven-induced arrest
was markedly abrogated when ATM had been immunode-
pleted from egg extracts, suggesting that Aven acts, at least
in part, through ATM activation (Figure 3E). Moreover, as
shown in Figure 3F, expression of human Aven in egg extracts
promoted an electrophoretic shift in Chk2 (indicative of activa-
tion) commensurate with the shift promoted by DNA bearing
double-stranded breaks (DSB). The addition of either human
Aven or DSB DNA to extracts also promoted commensurate
phosphorylation of p53 at a known site of ATM-catalyzed
phosphorylation (S15) (Figure S2). We also found that the abil-
ity of endogenous Aven to coimmunoprecipitate with ATM
from HeLa cell nuclear extracts was markedly increased by
pretreatment of cells with the radiomimetic drug neocarzinos-
tatin (NCS) (Figure 3G; although some ATM signal is seen in
mock immunoprecipitates, this signal is NCS-insenstive and
substantially weaker than that seen in the Aven precipitate
from NCS-treated cells). Moreover, Aven could bind to plasmid
DNA only after it had been linearized, suggesting that Aven
might have affinity for DSB DNA (Figure 3H).
Although Aven could promote phosphorylation of ATM sub-
strates and induce cell-cycle arrest, it was not clear whether
Aven acted upstream of ATM to promote its activation rather
than at the level of the substrate(s). To address this, we exam-
ined phosphorylation of ATM itself at S1981, a site that is auto
(or trans)-phosphorylated in response to DNA damage. Be-
cause it was possible that Aven addition promoted DNA dam-
age to trigger ATM activation indirectly, we examined S1981
phosphorylation in extracts lacking DNA but supplemented
with Aven. As shown in Figure 3I, Aven addition promoted en-
dogenous ATM S1981 phosphorylation, as seen after the addi-
tion of DSB DNA. Moreover, this S1981-phosphorylation signal
was overridden by caffeine and reduced by ATM depletion,
consistent with Aven’s ability to promote ATM autophosphor-
ylation (Figure 3I and Figure S3). Virtually identical results were
obtained when a recombinant fragment that includes the ATM-
S1981 site (GST-ATM aa1905–2100) was added to extracts
as a trans substrate of endogenous ATM (Figure S4). These
data demonstrate that Aven addition to egg extracts triggers
ATM activation to promote G2/M arrest. Furthermore, Aven
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(A) Left panel: 1 ml (4 U) of purified Cdc2/Cyclin B kinase was incubated with 80 nm His-DN72hAven protein or GST control, radiolabeled ATP, and Histone H1
substrate. Samples were taken at the indicated time points and assayed for histone H1-directed kinase activity and quantified. Right panel: 1 ml (4 U) of
purified Cdc2/Cyclin B kinase was incubated with His-DN72hAven protein or His-GST control at different concentrations for 30 min and assayed for histone
H1-directed kinase activity.
(B) Interphase extracts were incubated with His-DN72hAven protein or His-GST control for 30 min. Nondegradable cyclinB1 was then added to the extracts,
and aliquots were taken at the indicated times for immunoblotting with anti-pCdc2Y15.
(C) His-DN72hAven protein, together with GST-Cdc25 coupled to glutathione beads, was incubated in interphase egg extract for 30 min. After the addition of
nondegradable CyclinB1, GST-Cdc25 beads were retrieved and washed at the indicated times and immunoblotted with anti-14-3-33 antibody. In addition,
aliquots were taken at the same time points and immunoblotting was performed with anti-pCdc25T138, anti-pCdc25S287, or anti-pCdc2Y15 antibody.
(D) Cycling extracts were incubated with mRNA encoding hAven or with hAven and WT Cdc25 or Cdc25S287A. Samples were taken at the indicated times
and immunoblotted with anti-pCdc2Y15 antibody.
(E and F) His-DN72hAven protein or GST control protein was added to mitotic extracts; aliquots were taken at the indicated times and assayed for their ability
to phosphorylate histone H1 or immunoblotted with anti-pCdc2Y15 antibody.overexpression acted synergistically with DSB DNA in Xeno-
pus egg extracts or the radiomimetic drug neocarzinostatin
(NCS) to induce ATM S1981 phosphorylation in Hela cells
(Figures 3J and 3K, respectively), consistent with the notion
that Aven contributes to ATM activation in response to DNA
damage.Aven is Required for DNA-Damage-Induced
Inhibition of Mitotic Entry
Although exogenous Aven appeared to promote ATM activa-
tion in the absence of DNA damage, we wished to determine
whether Aven was required for activation of ATM by endo-
genous DNA-responsive-checkpoint pathways. Addition of
Aven Activates ATM in the DNA-Damage Response
937Figure 3. DNA-Damage-Checkpoint-Pathway Components are Involved in Aven-Induced Delay of Mitotic Entry
(A and B) mRNA encoding DN72hAven or control buffer was added to cycling extracts 6 UCN-01 (5 ng/ul) or caffeine (5 mM). Aliquots were taken at the
indicated times and immunoblotted with anti-pCdc2Y15 antibody.
(C) DN72hAven was transfected into 293T cells with or without Flag-tagged full-length ATM. Cell lysates and anti-Flag immunoprecipitates were separated
by SDS-PAGE and analyzed by immunoblotting with the indicated antibodies.
(D) Glutathione beads coupled to GST, GST-DN72hAven, or GST-xAven were incubated in interphase extracts depleted with xATM antibody or control IgG
for 1 hr at room temperature and then retrieved, washed, and immunoblotted with anti-xATM antibody.
(E) Left panel: cycling extracts were immunodepleted with anti-xATM or control IgG, and aliquots were immunoblotted with anti-xATM antibody. Right panel:
hAven mRNA was incubated in cycling extracts immunodepleted of ATM or mock-depleted with IgG. Samples were taken at the indicated times and
immunoblotted with anti-pCdc2Y15 antibody.
(F) Cycling extracts were supplemented with either buffer, hAven mRNA, or DNA bearing double-stranded breaks (DSB) in the presence of 35S-labeled Chk26
caffeine (5 mM) for 1 hr. Aliquots were resolved by SDS-PAGE, and Chk2 electrophoretic mobility was examined with the use of a phosphoimager.
(G) HeLa cells treated with or without NCS (200 ng/ml) for 1hr were harvested to make nuclear fractions. Rabbit anti-Aven antibody or control IgG immuno-
precipitates were immunoblotted with the indicated antibodies.
(H) Circular pGEX-KG-Emi2 or Not-I cut linear pGEX-KG-Emi2 plasmid was incubated in the interphase extracts for 30min. Anti-Xenopus Aven antibody or
control IgG was used for immunoprecipitation and washed immunoprecipitates were used as PCR templates to detect DNA binding to Xenopus Aven.
(I) Cycling extracts were supplemented with buffer control, DSB DNA, or mRNA encoding full-length hAven, DN72hAven, or full-length xAven +/2 caffeine
(5mM) for 1hr. Samples were taken and immunoblotted with anti-pATM S1981 antibody.
(J) Top panel: buffer control, 10 ng of (dA-dT)70, 10 ng of (dA-dT)70 with mRNA encoding DN72hAven, or mRNA encoding DN72hAven was added to cycling
extracts. After 1hr, samples were immunoblotted with the indicated antibodies. Bottom panel: the amount of pATM S1981 was quantified, normalized, and
plotted. Error bars represent the standard deviation of three replicate experiments.
(K) HeLa cell transfected with vector control or Aven were treated with NCS (200 ng/ml) for 10 or 30 min. Cell lysates were resolved by SDS-PAGE and
immunoblotted with the indicated antibodies.
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(A) Left panel: Anti-xAven immunoblotting of cycling extracts before and after depletion of Xenopus Aven by three sequential incubations with IgG or anti-
xAven antibody at 4C. Right panel: immunoblot of Aven- or mock-depleted extracts with anti-pCdc2Y15 antibody following addition of 10 ng/ml (dA-dT)70;
aliquots were removed at the indicated times.
(B) Left panel: immunoblot for xAven in depleted extracts (as in A) with subsequent addition of buffer control, mRNA for human or Xenopus Aven. Note that
anti-xAven antibody weakly recognizes hAven in cycling extracts. Right Panel: immunoblotting of the same extracts with anti-pCdc2Y15 antibody at the
indicated times following addition of 10 ng/ml (dA-dT)70.
(C) HeLa cells treated with NCS (200 ng/ml) for 30 min were stained with anti-pATM S1981(green), anti-pH2AX (red) or with DAPI (blue) to stain DNA. Yellow
coloring indicates colocalization of pATM S1981 and pH2AX.
(D) Top left panel: immunoblotting of human Aven in HeLa cells transfected with control siRNA or pooled hAven siRNAs with anti-hAven antibody. Actin
serves as a loading control. Top right and bottom left panels: control or hAven siRNA-transfected HeLa cells were incubated with NCS (200 ng/ml) for
30 min and stained with anti-pATM S1981 (green) or with DAPI to stain DNA (blue). Top right panel shows a single high magnification nucleus; pATM
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939(dA-dT)70 promotes robust activation of DNA-responsive
checkpoints in egg extracts [32], resulting in stabilization of
inhibitory Y15 phosphorylation of Cdc2. In contrast, immuno-
depletion of endogenous Aven protein allowed entry (albeit
delayed) into mitosis even in the face of checkpoint activation
(Figure 4A). To rule out the possibility that removal of Aven co-
depleted an associated protein that allowed DNA-damage-
checkpoint override, Aven was added back to extracts after
immunodepletion. When mRNA for either human or Xenopus
Aven was added back to Aven-depleted extracts, (dA-dT)70-
induced-checkpoint activation was restored (Figure 4B).
In response to DNA damage, ATM is phosphorylated at
S1981 and is localized in foci, which can be detected as punc-
tate staining by immunofluorescence [25, 45]. To examine the
role of Aven in checkpoint-induced ATM activation in a mam-
malian system, we utilized RNAi interference (pooled oligonu-
cleotides) to knock down the expression of endogenous
human Aven in HeLa cells and monitored the activation status
of ATM upon addition of the radiomimetic drug neocarzinosta-
tin (NCS). As shown in Figure 4C, NCS-treated HeLa cells dis-
played discrete foci of phospho-ATM that colocalized with
phospho-H2AX. Remarkably, the phospho-ATM signal was
absent from cells ablated for Aven by RNA interference (Fig-
ure 4D). These data strongly suggest that ATM could not be
activated or that the activation could not be sustained in the
absence of Aven. These findings were confirmed by immuno-
blotting of pATM S1981, given that depletion of Aven abolished
detectable autophosphorylation on S1981 of ATM in response
to DNA damage (Figure 4E). To further validate these findings,
individual siRNAs from the pool were used to knock down
Aven; two different oligonucleotides that decreased Aven
levels dampened the appearance of S1981 phosphorylation
in response to NCS (Figure 4F; note that the Aven knockdown
in these experiments is not complete). These data reinforce
the conclusion that Aven is required for the linking of DNA
damage to ATM activation.
ATM Phosphorylates and Activates Aven
in a Positive Feedback Loop
Positive and negative feedback loops are common in cell-
cycle-regulatory networks [1, 2, 16, 46, 47]. Hence, we sought
to determine whether Aven, in addition to its role as a modulator
of the ATM pathway, might also be a substrate of ATM. Indeed,
activation of the DNA-damage checkpoint with DSB DNA, but
not of the replication checkpoint with aphidicolin-treated nu-
clei, enhanced phosphorylation of Aven in egg extracts, an
effect that could be abrogated by the addition of caffeine
(Figure 5A); the addition of KU55933, an ATM-specific inhibitor
(Figure S5); or the immunodepletion of ATM (Figure S6). In ad-
dition, active ATM immunoprecipitated from 293T cells could
phosphorylate Aven in vitro, and this phosphorylation was
largely inhibited by treatment with wortmannin, an inhibitor of
PI3K-family kinases (Figure 5B). Moreover, when ATM was
immunodepleted from extracts, Aven phosphorylation by
ATM immunoprecipitates was largely abrogated (Figure S7).
ATM typically phosphorylates serine residues followed by
glutamine (SQ sites) [48], and analysis of the amino acid se-
quence of human Aven revealed four such motifs located atresidues S135, 153, 268, and 308. To study the potential effect
of ATM-mediated phosphorylation on Aven function, we mu-
tated these four SQ sites to AQ and analyzed the phosphoryla-
tion status of the resulting mutant. As shown in Figure 5C and
Figure S5, DSB DNA enhanced Aven phosphorylation over
time, and mutation of all four putative ATM-phosphorylation
sites largely eliminated the DSB-DNA-enhanced phosphoryla-
tion of Aven (though basal phosphorylation remained). We per-
formed mass spectrometry on recombinant Aven protein that
had been dipped into egg extracts treated with or without DSB
DNA and identified S135 and S308 as conserved sites of phos-
phorylation (Figure 5D and Figure S9). To confirm the signifi-
cance of these two phospho-SQ sites, we mutated these to
AQ and performed an in vitro ATM kinase assay using ATM im-
munoprecipitated from Xenopus egg extracts. We found that
mutating S135 and S308 sites to Alanine largely dampened Av-
en’s phosphorylation by ATM (though some phosphorylation
remained, due to either a contaminating kinase or an unidenti-
fied ATM-phosphorylation site). However, it is noteworthy that
we did not observe any additional decrease in phosphorylation
when we changed S153 or S268 to Alanine (Figure 5E and
Figure S10), consistent with our mass-spectrometric identifi-
cation of phospho-S135 and -S308 following ATM activation.
To analyze the effects of Aven phosphorylation, we added
mRNA encoding either WT or nonphosphorylatable (S135,
308A) mutant Aven to cycling egg extracts and monitored mi-
totic entry. Mutant Aven protein was partially active, but it
failed to maintain the cell-cycle arrest observed with similar
levels of WT Aven (Figure 5F). These data suggest that Aven
overexpression can activate ATM and that Aven phosphoryla-
tion in a positive feedback loop enforces Aven activity, making
it a more potent ATM activator.
Discussion
The results described here implicate Aven as a key regulator of
the G2/M DNA-damage checkpoint. Aven’s ability to prevent
M-phase entry stems from its ability to activate ATM to pro-
mote phosphorylation and activation of cell-cycle inhibitors
(e.g., Chk2) controlling Cdc2/Cyclin B (see model, Figure 6).
Precisely how Aven is engaged after DNA damage remains
to be determined, but it is clear that the absence of Aven
impairs checkpoint-mediated ATM function.
Aven-Mediated ATM Activation
Because Aven interacted with ATM and induced ATM S1981
phosphorylation, Aven protein might initiate activation of
ATM (i.e., recruitment to sites of DNA damage, monomeriza-
tion, and autophosphorylation). Although we did not detect
Aven interaction with MRN complex, we have noticed that
Aven protein binds efficiently to restriction-enzyme-digested
plasmids but not to intact plasmids added to egg extracts.
In addition, the endogenous Aven-ATM interaction was in-
creased after DNA damage, suggesting that Aven might be
involved in ATM recruitment to sites of double-stranded DNA
breaks or that double-stranded breaks provide a platform for
Aven-mediated ATM activation. Alternatively, Aven might in-
hibit ATM S1981 dephosphorylation, thereby interfering withS1981 staining of a larger field of cells is shown on the bottom left. Bottom right: Columns represent the average of pATM S1981 positive cells from three
replicate experiments and error bars represent the standard deviation.
(E) anti-pATM S1981 immunoblots of HeLa cells transfected with control siRNA, or pooled hAven siRNAs and treated +/2 100 or 1000 ng/ml of NCS. Hsp90a
was used as a loading control.
(F) Immunoblots of HeLa cells transfected with single hAven siRNAs (a or b) or control siRNA and treated +/2NCS (200 ng/ml) with the indicated antibodies.
Current Biology Vol 18 No 13
940Figure 5. Positive Feedback Activation of Aven
by Phosphorylation
(A) GST-DN72hAven coupled to glutathione
beads were dipped into interphase egg extracts
pre-treated with DSB or sperm chromatin and
Aphidicolin (APH) in the presence of [g-32P] ATP
+/2 caffeine (5mM) for 15 min, then retrieved,
washed, and resolved on 10% SDS-PAGE. Phos-
phorylated hAven was detected with the use of
a phosphoimager.
(B) ATM kinase was immunoprecipitated from
293T cells treated withNCS +/2wortmanninusing
anti-ATM antibody coupled to protein A sephar-
ose beads. Purified His-DN72hAven protein was
then incubated with the immunoprecipitates in ki-
nase buffer for 30 min and resolved by SDS-PAGE.
PHAS-1, a known ATM substrate, and BSA were
included as positive and negative controls, re-
spectively. Phosphorylation was detected with
the use of a phosphoimager.
(C) Left panel: GST-DN72hAven WT or S135,
153, 268, 308A mutant protein conjugated
to glutathione beads were dipped into interphase
extracts in the presence of [g-32P] ATP. Extracts
were then treated with DSB and aliquots were
taken at the indicated times and assayed as (A).
Right panel: the amount of Aven SQ phosphoryla-
tion was quantified, normalized, and plotted.
Error bars represent standard deviation of three
replicate experiments.
(D) GST-DN72hAven WT or S135, 153, 268, 308A
protein was incubated in interphase extracts -
(left) or + (middle and right) DSB DNA. After incu-
bation, the protein was retrieved on glutathione
Sepharose beads and resolved by SDS-PAGE,
and the relevant bands were excised from the
gel, trypsin digested, and analyzed by LC/MS
mass spectrometry. LC/MS-extracted ion chro-
matograms (EIC) of unphosphorylated (0xP) and
presumed monophosphorylated (1xP) tryptic
peptides were examined, and EIC peaks (middle;
at 2.6 and 11.5 min in the 1xP traces) indicate the
phosphorylation of the tryptic peptides upon
DSB DNA treatment. Such peaks were not de-
tected in the tryptic peptides derived from the
GST-AN72hAven S135, 153, 268, 308A protein
(right), indicating a lack of phosphorylation.
(E) Left panel: xATM kinase was immunoprecipi-
tated from interphase extracts pretreated with
DSB. Purified GST-DN72hAven WT or AQ mutant
proteins were incubated with the immunoprecip-
itates in the kinase buffer for 30 min and assayed
as (A). Right panel: the amount of Aven SQ phos-
phorylation was quantified, normalized, and plot-
ted. Error bars represent standard deviation of
three replicate experiments (t test, p < 0.05).
(F) mRNA-encoding DN72hAven or DN72h-
AvenS135, 308A was added to the cycling ex-
tracts, and aliquots were taken at the indicated
times and immunoblotted with anti-pCdc2Y15
antibody.maintenance of ATM activity. Both PP2A and Wip1 dephos-
phorylate ATM S1981 [49, 50]. However, we have not observed
any direct interaction of Aven with PP2A or Wip1, nor have we
seen alterations in overall PP2A activity in egg extracts supple-
mented with Aven (data not shown). It has also been reported
that protein phosphatase 5 (PP5) is required for ATM activa-
tion, so it is plausible that Aven could activate PP5 or inactivate
a PP5 inhibitor [51].A Positive Feedback Loop Linking ATM and Aven
Depletion of Aven in both mammalian and Xenopus systems
compromised DNA-damage-induced ATM activation, and
overexpression of Aven prevented mitotic entry in egg ex-
tracts. We propose that overexpression of Aven mimics a sig-
naling pathway that would normally be engaged after DNA
damage. After ATM activation by DSB or Aven overproduction,
ATM may then phosphorylate Aven, enhancing Aven-mediated
Aven Activates ATM in the DNA-Damage Response
941ATM activation. After DNA damage, it might be that low-level
ATM activation promotes Aven phosphorylation, leading to
higher ATM activation. The impaired ability of the SQ mutant
Aven to promote cell-cycle arrest and ATM activation is consis-
tent with a role for these SQ phosphorylation sites in controlling
Aven function.
Although Aven could be phosphorylated by ATM, basal
phosphorylation of Aven was also evident when we incubated
GST-Aven protein with egg extracts. Mass-spectrometric
analysis of Aven dipped into egg extracts demonstrated basal
phosphorylation on Ser and Thr sites, in addition to the SQ
sites mentioned here (J.Y.G., M.Z.W., and S.K., unpublished
data). Thus, other kinases and/or pathways might contribute
to Aven phosphorylation, potentially providing additional in-
puts to Aven regulation.
Figure 6. Aven’s Role in DNA-Damage-Induced ATM Activation and G2/M
Arrest
During DNA damage, Aven serves as a signal transducer in the ATM acti-
vation pathway. Activated ATM in turn phosphorylates Aven on S135 and
S308, and causes full activation of Aven. Fully activated Aven then further
enhances ATM activation, leading to activation of downstream pathway
components to inhibit Cdc25 activation and enhance Wee1/Myt kinase
activity, leading to Cdc2/CyclinB inactivation and inhibition of mitotic
entry.A Dual Regulator of Cell-Cycle and Apoptotic Progression
Although Aven was reported as an apoptotic regulator, we do
not know whether its cell-cycle- and apoptotic-modulatory
properties stem from the same underlying biochemical activ-
ity. It would be interesting to determine whether ATM is re-
quired for Aven’s modulation of the apoptosome. Conversely,
it will be of interest to determine whether Aven mutants that
cannot modulate apoptosis can influence cell-cycle progres-
sion. Aven might require entirely different domains and/or
functions to regulate cell division and apoptosis. In this regard,
it is of interest that Apaf-1 was recently reported to induce
S-phase arrest after DNA damage [52]. Although Aven has
been shown to be an apoptosome regulator and Apaf-1 inter-
actor ([36] and P.M.I. and J.M.H., unpublished data), Apaf-1
was reported not to be required for ATM S1981 phosphoryla-
tion and activation, whereas Aven binds ATM and promotes
its activation. Thus, Aven and Apaf-1 might act at different
points in checkpoint control. Indeed, it could be that Apaf-1
is required for the intra-S phase but not for the G2/M check-
point. It would be of significant interest to determine whether
extensive DNA damage alleviates Aven’s apoptotic-inhibitory
functions. Regardless of its precise mechanism of action,
Aven is ideally situated, as a mediator of both cell-cycle pro-
gression and cell death, to participate in the cellular decision
to live or die after DNA damage.
Supplemental Data
Experimental Procedures and ten supplemental figures are available online
at http://www.current-biology.com/cgi/content/full/18/13/933/DC1/.
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